An interventional study of INFINITY-ICOPE programme in Frailty in Older Adults, Intrinsic Capacity and Age-related Functional Decline, sponsored by Sengkang General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Sengkang General Hospital · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.
Among the 28 studies in Frailty with a site in Singapore, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 20 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 26th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:
Changi General Hospital · Sites in Singapore
Ages 65+ · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 50–80
National University of Singapore · Sites in Singapore
Ages 60–85 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 60–85 · Healthy volunteers
National University Hospital, Singapore · Sites in Singapore
Ages 60+ · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 600 is above the median of 83 across 772 interventional studies indexed under Frailty.
Median enrollment 140 across the 21 interventional studies, 345 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 28 have an industry lead sponsor. The 10 most frequent:
Sengkang General Hospital is the lead sponsor of 16 studies on the registry; 10 are open to participants now.
Sengkang General Hospital has 3 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
6 of the studies in Frailty with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081191National University of SingaporeDose-response Effect of Community Dance Programme | 2026-12 |
| NCT06073106Tan Tock Seng HospitalTargeting Osteosarcopaenia and Multimorbidity for Frailty Prevention | 2027-01 |
| NCT07081282National University of SingaporePrecision Stratification for Frailty and Cognitive Decline | 2027-01-31 |
| NCT07205133Changi General HospitalA Randomized Controlled Trial Comparing Whole Body Vibration Therapy With Usual Care and Usual Care to Improve Muscle Health in Older Adults | 2027-03-31 |
| NCT07525583National University Hospital, SingaporeImplementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore | 2027-05-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Frailty with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this intervention study is to screen and identify frailty and decline in intrinsic capacity (physical and mental capacities) in community-dwelling older adults in Singapore, and to evaluate whether early identification and targeted interventions can improve health outcomes and support healthy ageing. The main questions it aims to answer are:
Participants will:
The INFINITY-ICOPE programme integrates the concepts of frailty and intrinsic capacity - a person's physical and mental abilities essential for maintaining overall health and well-being. Since intrinsic capacity represents the physiological reserves whose decline can lead to frailty, monitoring intrinsic capacity trajectories enables timely intervention to address deteriorating physical and mental capacities. The programmme employs a tiered approach to provide comprehensive geriatric assessment for frail older adults, utilizing technology-enabled tools including the SCREENii algorithmic approach for objective physical frailty assessment and the ENGAGE app to empower older individuals through self-screening, remote intrinsic capacity monitoring, and behavioural nudges.
The investigators primary aim is maintaining older adults' independence and community engagement, measured through life-space mobility. Secondary aims encompass promoting regular screening for frailty and intrinsic capacity decline, implementing early intervention strategies, enhancing quality of life, and developing a cost-effective healthcare delivery model. INFINITY-ICOPE follows the implementation research logic model to ensure rigorous and replicable research. The study comprises 4 phases:
Phase 1 (Proof-of-Concept) - 12 months. This preparatory phase focuses on 3 key areas: technology readiness, care pathway development, and stakeholder readiness assessment.
Phase 3 (Testing-bed) - 30 months. This study employs a pragmatic controlled design with 540 older adults across 8 eldercare and/or active ageing centres within SingHealth zones. Intervention design: The INFINITY-ICOPE programme includes integrated frailty and intrinsic capacity screening, targeted referrals based on stratification, and 6-monthly self-monitoring via ENGAGE app and SCREENii. Participants are stratified into 3 groups post-screening: (a) Frail (regardless of intrinsic capacity status); (b) Non-frail with declining intrinsic capacity; and (c) Non-frail with intact intrinsic capacity.
Targeted interventions: Frail participants (Fried score of 3 and above) receive comprehensive geriatric assessment at geriatric specialty hubs, whilst non-frail participants with intrinsic capacity decline undergo Steps 2 to 3 assessments at Community Health Posts with personalized interventions. All intervention participants receive ENGAGE app notifications including appointment reminders, lifestyle nudges, and screening prompts. Additional cognitive assessment via Cognify (30-minute automated battery) validated cognitive screening for enhanced stratification. Control group: Continues usual activities with wait-list access to INFINITYICOPE after 12-month outcomes assessment, enabling centres to scale the programme as standard care. Data collection: Comprehensive measures collected at 6-monthly intervals include socio-demographics, frailty / sarcopenia / intrinsic capacity status, medical comorbidities, functional performance, cognitive / mood assessments, quality of life, and intervention adherence, emphasizing both clinical and implementation effectiveness for sustainability evaluation.
Inclusion Criteria: (in Phases 1, 2 and 3):
Exclusion Criteria (in Phases 1, 2 and 3):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application.
Other: INFINITY-ICOPE programme
Participants will continue usual care at active ageing centres and receive the same interventions after their 12-month assessment.
Other: INFINITY-ICOPE programme
The INFINITY-ICOPE programme will involve (i) integrated frailty and intrinsic capacity screening, (ii) referral to comprehensive geriatric assessment for frail participants or pathways adapted from the WHO-ICOPE approach for non-frail seniors with intrinsic capacity decline, (iii) 6-monthly self-monitoring for IC and frailty supported through the ENGAGE app and SCREENii.
Life space mobility
To maintain functional independence in older adults, represented by life space mobility (LSM). LSM will be assessed using the University of Alabama Life Space Assessment (LSA) questionnaire. This tool measures the extent of an older adult's movement within their environment, reflecting their community participation and functional independence. The outcome will be expressed as the LSM score, a numerical value derived from the LSA questionnaire, indicating the spatial extent and frequency of movement over the last 4 weeks.
Time frame: From enrollment to the end of intervention at 12 months.
Community implementation outcomes of INFINITY-ICOPE programme
Fidelity: Measured by adherence rates (%) to protocol specifications and intervention delivery as intended, assessed through structured fidelity checklists completed by implementation staff. Penetration: Measured as the proportion (%) of eligible older adults reached and enrolled from target community settings, based on programme enrollment records. Sustainability: Measured by the continued operation of the programme and ongoing partner engagement, assessed through documentation of programme activities and partner participation rates (%) beyond the initial implementation period. Follow-up telephone interviews will be conducted at 3 and 9 months post-enrollment to assess participants' self-reported adherence using a standardized questionnaire. Pre- and post-screening surveys with community and primary care providers will evaluate their experience with the INFINITY-ICOPE programme through Likert-scale items, informing programme refinements.
Time frame: Fidelity: Assessed continuously throughout the 24-month study period. Penetration: Measured at 12 months and 24 months. Sustainability: Evaluated at 24 months and 6 months post-study completion (30 months total).
Adherence to automated frailty screening and remote intrinsic capacity monitoring
Proportion of participants who complete regular screening assessments using SCREENii technology and engage with remote monitoring through the ENGAGE app, measured by frequency of use, completion rates, and sustained engagement over time.
Time frame: Assessed at baseline, 6, 12, and 24 months.
Prevention of frailty progression and preservation of intrinsic capacity
Changes in frailty status and intrinsic capacity status across the 6 domains (mobility, cognition, mental health, hearing, vision, nutrition) following tiered screening and early intervention. Frailty status will be measured using the Fried Frailty Phenotype, reported as the proportion (%) of participants classified as frail, pre-frail, or robust. Intrinsic capacity will be evaluated using the ICOPE Step 1 screening followed by Step 2 clarification assessments for each domain: Mobility: Short Physical Performance Battery (SPPB) score (range 0-12) Cognition: Chinese Mini Mental State Examination (CMMSE) score and a single self-reported memory concern question (presence or absence) Mental health: Geriatric Depression Scale-15 (GDS-15) score Hearing: Screening audiometer results (threshold levels in decibels) Vision: Visual acuity test results using handheld Snellen chart Nutrition: Mini Nutritional Assessment Short Form (MNA-SF) score
Time frame: Assessed at baseline, 6, 12, and 24 months.
Health-related quality of life improvement
Changes in validated quality of life measures using EuroQol 5-dimension (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ-VAS) following INFINITY-ICOPE intervention. For EQ-5D-5L, participants indicate their health by selecting one level in each of five dimensions (mobility, self-care, usual activities, pain / discomfort, anxiety / depression), producing a 5-digit code representing their health state. The EQ-VAS records self-rated health on a 0-100 scale, with endpoints labeled 'best' and 'worst' imaginable health, providing a quantitative measure of perceived health.
Time frame: Assessed at baseline, 6, 12, and 24 months.
Healthcare service utilization
Healthcare service utilization will be assessed by the number of emergency department (ED) visits and hospitalizations occurring within the past 6 months or 1 year, depending on the timing of the study visit. The reasons for each ED visit and hospitalization will also be recorded. These measures will be compared between the intervention and control groups.
Time frame: Assessed at baseline, 6, 12, and 24 months.
Association between oral frailty and physical frailty for risk stratification
Oral frailty will be assessed using the Oral Frailty Index-8 (OFI-8), which provides a score indicating the degree of oral frailty. The higher the OFI-8 score, the higher the risk of frailty, i.e., 0-2 points indicates low risk; 3 points indicates moderate risk; and greater than 4 points indicates high risk. Physical frailty will be measured using the Fried Frailty Phenotype, categorizing participants as frail, pre-frail, or robust based on established criteria. The outcome will be the correlation between the OFI-8 score and physical frailty status, analyzed to identify relationships that may improve risk stratification and guide targeted interventions within the INFINITY-ICOPE framework.
Time frame: Assessed at baseline, 6, 12, and 24 months.
Plan to share: Undecided — IPD sharing with other researchers is not planned at this time. The research team will evaluate potential data sharing opportunities following study completion, subject to ethical approval, participant consent provisions, and establishment of secure data sharing protocols that maintain participant confidentiality.
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 47 months is above that.
Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sengkang General Hospital